362-86-7

Usage

Uses

Used in Pharmaceutical Industry:
Flurbiprofen is utilized as an analgesic and anti-inflammatory agent for the treatment of various conditions, including arthritis, menstrual cramps, and other types of pain. It is available in both prescription and over-the-counter forms, making it accessible for a wide range of patients.
Used in Pain Management:
Flurbiprofen serves as an effective pain reliever, targeting the prostaglandins that cause discomfort and inflammation. This makes it a valuable option for individuals seeking relief from various types of pain.
Used in Inflammation Reduction:
Due to its ability to inhibit prostaglandin production, flurbiprofen is also used to reduce inflammation associated with different conditions, providing relief and improving the quality of life for those affected.
It is important to use flurbiprofen as directed and to consult a healthcare professional before using it, especially if you have any underlying health conditions or are taking other medications. While generally well tolerated, it may cause side effects such as gastrointestinal discomfort and an increased risk of cardiovascular events with prolonged use.

InChI:InChI=1/C15H13FO2/c16-13-8-6-12(7-9-13)14(10-15(17)18)11-4-2-1-3-5-11/h1-9,14H,10H2,(H,17,18)

Upstream product

• 462-06-6 fluorobenzene 
• 140-10-3 (E)-3-phenylacrylic acid 
• 390-42-1 (E/Z)-3-(4-fluorophenyl)-3-phenylpropenoic acid 
• 365-21-9 1-(chlorophenylmethyl)-4-fluorobenzene 
• 2025-40-3 ethyl benzylidenecyanoacetate 
• 100-52-7 benzaldehyde 
• 395-21-1 1-(4-fluorophenyl)-1-phenylethylene 
• 19334-70-4 3-Hydroxy-3-phenyl-3-<4-fluor-phenyl>-propionsaeure 
• 428-00-2 3-(4-fluoro-phenyl)-3-hydroxy-3-phenyl-propionic acid ethyl ester 
• 621-82-9 Cinnamic acid 
• 459-32-5 4-fluorocinnamic acid 
• 98-80-6 phenylboronic acid 
• 1765-93-1 4-fluoroboronic acid 
• 3495-36-1 cesium formate 

Downstream Products

• 85662-85-7 3-(4-fluorophenyl)-2,3-dihydro-1H-indene-1-one 
• 374724-94-4 3-(4-fluorophenyl)-3-phenylpropan-1-ol 
• 80273-08-1 Lu 17-123 
• 104087-10-7 1-chloro-4-(4-flurophenyl)indan 
• 80272-55-5 cis-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-ol 
• 1026728-00-6 2-(2-{2-[3-(4-fluoro-phenyl)-3-phenyl-propyl]-1H-imidazol-4-yl}-ethyl)-isoindole-1,3-dione 

Relevant academic research and scientific papers

Photoredox Activation of Formate Salts: Hydrocarboxylation of Alkenes via Carboxyl Group Transfer

A photoredox activation mode of formate salts for carboxylation was developed. Using a formate salt as the reductant, carbonyl source, and hydrogen atom transfer reagent, a wide range of alkenes can be converted into acid products via a carboxyl group tra

Covalent organic framework supported Pd(II)-catalyzed conjugate additions of arylboronic acids to α,β-unsaturated carboxylic acids

A palladium(II)-coordinated covalent organic framework (Pd(II)@COF) was mechanochemically synthesized from [2,2′-bipyridine]-5,5′-diamine (Bpy) and 1,3,5-triformylphloroglucinol (Tp), which was demonstrated as a catalyst for conjugate addition of arylboronic acids to unreactive α,β-unsaturated carboxylic acids in aqueous media (water/acetone = 1:1). Modest to good yields were obtained for most substrates, and studies on the catalyst recyclability showed that the heterogeneous catalyst gave >80% yields in the first 4 cycles. This research broadens the application of COFs supported catalysis and gave a new option for Pd(II)-catalysis.

Synthesis method of succinic acid derivative or 3 -arylpropionic acid (by machine translation)

The invention discloses a synthesis method of a succinic acid derivative or 3 -arylpropionic acid, which comprises the following steps: adding a base in a drying reaction tube and CO removing CO. 2 The reaction is carried out under the irradiation of visible light, the reaction is carried out under visible light irradiation, and then separation and purification are carried out to obtain the butanedioic acid derivative or 3 -arylpropionic acid product; the base comprises sodium tert-butoxide, potassium tert-butoxide, lithium tert-butyl alcohol and 4 - potassium carbonate; and the reaction substrate comprises an acrylate compound or an aryl vinyl compound. CO can be induced by visible light. 2 The scheme provided by the invention is mild in reaction condition and wide in reaction 3 - substrate selectivity, and the reaction substrate is wide in selectivity, the raw materials are cheap and easily available, and the method has a good industrial application prospect. (by machine translation)

Cationic Pd(II)/bipyridine-catalyzed conjugate addition of arylboronic acids to α,β-unsaturated carboxylic acids in aqueous media

An in-situ generated cationic Pd(II)/bipyridine-catalyzed conjugate addition of arylboronic acids to α,β-unsaturated carboxylic acids in water was developed and optimized. For most substrates, nearly quantitative yields were given, and the products can be purified by simple washing without column chromatography. The reaction can be scaled up to 1.0 g easily with excellent yields. Also the loading of catalyst can be lowered to 1.0 mol% with modest yields, and the reaction provided a mild and easy way to synthesize β-disubstituted carboxylic acids.

Pd(II)/Bipyridine-Catalyzed Conjugate Addition of Arylboronic Acids to α,β-Unsaturated Carboxylic Acids. Synthesis of β-Quaternary Carbons Substituted Carboxylic Acids

Pd(II)/bipyridine-catalyzed conjugate addition of arylboronic acids to α,β-unsaturated carboxylic acids (including β,β-disubstituted acrylic acids) was developed and optimized, which provided a mild and convenient method for the highly challenging synthesis of β-quaternary carbons substituted carboxylic acids.

BTISA-catalyzed Friedel-Crafts bimolecular cyclization of cinnamic acid under superelectrophilic solvation conditions

Friedel-Crafts bimolecular cyclizations of cinnamic acid and cinnamoyl chloride with aromatic compounds in strong and superstrong acids in present of 1 mol% BTISA were investigated. It was demonstrated that catalytic amounts of this new superacid have essential effect on such type of reactions. Its use makes possible the preparation of indanones with quantitative yields.

Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine h2 receptor agonists

N1-Aryl(heteroaryl)alkyl-N2-[3-(1H-imidazol-4-yl) propyl]guanidines are potent histamine H2-receptor (H2R) agonists, but their applicability is compromised by the lack of oral bioavailability and CNS penetration. To improve pharmacokinetics, we introduced carbonyl instead of methylene adjacent to the guanidine moiety, decreasing the basicity of the novel H2R agonists by 4-5 orders of magnitude. Some acylguanidines with one phenyl ring were even more potent than their diaryl analogues. As demonstrated by HPLC-MS, the acylguanidines (bioisosteres of the alkylguanidines) were absorbed from the gut of mice and detected in brain. In GTPase assays using recombinant receptors, acylguanidines were more potent at the guinea pig than at the human H2R. At the hH1R and hH3R, the compounds were weak to moderate antagonists or partial agonists. Moreover, potent partial hH4R agonists were identified. Receptor subtype selectivity depends on the imidazolylpropylguanidine moiety (privileged structure), opening an avenue to distinct pharmacological tools including potent H4R agonists.

Ring-substituted histaprodifen analogues as partial agonists for histamine H1 receptors: Synthesis and structure-activity relationships

Thirteen racemic benzene ring-substituted analogues of histaprodifen (8a; 2-[2-(3,3-diphenylpropyl)-1H-imidazol-4-yl]ethanamine), a novel lead for potent and selective histamine H1-receptor agonists, have been prepared from substituted 4,4-diphenylbutyronitriles 5 via cyclization of the corresponding methyl butyrimidates 6 with 2-oxo-4-phthalimido-1-butyl acetate in liquid ammonia, followed by deprotection. Nitriles 5 were accessible by alkylation of either substituted diphenylmethanes with 3-bromopropionitrile or diethyl malonate with substituted 1-chloro-diphenylmethanes and subsequent standard reactions. The title compounds 8 displayed partial agonism on conctractile H1 receptors of the guinea-pig ileum (E(max) = 2-98% relative to histamine) and, compared with the endogenous agonist, were endowed with agonist potencies of 4-92%. The meta fluorinated (8c) and meta chlorinated (8f) analogues showed the highest relative potency in this series (95% confidence limits 85-99% and 78-102%), but did not exceed the value of the lead 8a (99- 124%). Compound 8c (2-[2-[3-(3-fluorophenyl)-3-phenylpropyl]-1H-imidazol-4- yl]ethanamine) was a partial agonist at contractile H1 receptors of the guinea-pig aorta (relative potency 154% vs. 100% for histamine) and at relaxation-mediating endothelial H1 receptors of the rat aorta (relative potency 556% vs. 100% for histamine) and matched with the functional behaviour of 8a. Agonism observed for each compound was sensitive to blockade by the selective H1-receptor antagonist mepyramine (pA2 ? 9 (guinea-pig) and pA2 ? 8 (rat aorta)). All histaprodifen analogues 8 stimulated neither histaminergic H2/H3 nor cholinergic M3 receptors. They displayed only low to moderate affinity for these sites (H2: pD'2 3/M3: pA2 1-receptor agonist, viz. 2- phenylhistamine. (C) 2000 Editions scientifiques et medicales Elsevier SAS.

Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans

A series of 1-piperazino-3-phenylindans was synthesized and tested for neuroleptic and thymoleptic activity. Neuroleptic activity was found only in trans racemates and was associated with one of the enantiomers only. The potent and long-acting neuroleptic compound trans-4-[3-(4-fluorophenyl)-6-(trifluoromethyl)indan-1-yl]-1-piperazineeth anol (Lu 18-012, tefludazine) was developed by systematic variation of structural components. Thymoleptic activity was optimized, especially with respect to dopamine-uptake inhibition. No geometrical stereoselectivity was found with regard to dopamine-uptake inhibition, but a high enantioselectivity could be demonstrated for both cis and trans racemates. The most potent compounds were 1-piperazino-3-(3,4-dichlorophenyl)indans with IC50 values of about 2 nM for inhibition of dopamine uptake.